To: CAHAN San Diego Participants  
Date: April 26, 2021  
From: Public Health Services  

Health Advisory Update #32: Coronavirus Disease 2019 (COVID-19) Vaccine Update

Key Messages

- Resume vaccination with Johnson & Johnson (Janssen) COVID-19 vaccine with informed consent on benefits and risks of this product.
- A Centers for Disease Control and Prevention (CDC) Clinician Outreach and Communication Activity (COCA) on the Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome is scheduled for April 27, 2021, 11:00 am – 12:00 pm (PST).

Situation

After additional review of available data on the risk of thrombosis with thrombocytopenia syndrome (TTS) presenting with Cerebral Venous Sinus Thrombosis (CVST), the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to lift the pause on the Janssen vaccine. Subsequently, the Food and Drug Administration (FDA) and CDC have issued a recommendation to lift pause on the Janssen vaccine. The Western States Scientific Safety Review Workgroup consensus was also that the risk of severe COVID-19 outweighed the risk of this rare complication at this point in the pandemic. For additional clinical information about the cases of TTS/CVST, please see the full CDC Health Alert. A CDC sponsored Clinician Outreach and Communication Activity (COCA) on this topic is scheduled for April 27, 2021, 11:00 am – 12:00 pm (PST): Call details (and later, the recording) are here.

Actions Requested

1. Resume vaccinations with the Janssen vaccine; providers should use the current version of the Janssen Vaccination Fact Sheet (CDPH version here) and discuss the benefits and risks of vaccination with their patients. The CDC has provided responses to frequently asked questions from the general public on the pause here.
2. Maintain suspicion for thrombosis with TTS in patients who present with signs and symptoms consistent with CVST or other thrombotic events and inquire about recent (within 3 weeks) vaccination for COVID-19.
3. Do not treat thrombotic thrombocytopenia with heparin unless an enzyme-linked immunosorbent (ELISA) assay for PF4 antibodies (heparin-induced thrombocytopenia or HIT test) is negative. Instead, consider non-heparin anticoagulants and high-dose intravenous immune globulin. See CAHAN #31 for additional information.
4. Report vaccine-related adverse events and deaths and vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS), and to the County Immunization Program at IZINFO.HHSA@sdcounty.ca.gov or Fax: (619) 692-5677.

Thank you for your participation.

CAHAN San Diego

County of San Diego Health & Human Services Agency  
Epidemiology and Immunization Services Branch  
Phone: (619) 692-8499; Fax: (858) 715-6458  
E-mail: cahan@sdcounty.ca.gov  
Public Website: http://www.cahansandiego.com

CAHAN San Diego Alerts are intended for the use of public health, medical and laboratory professionals in San Diego County. This alert has been approved for reproduction and distribution to interested professionals. An online CAHAN San Diego application is available at http://www.cahansandiego.com for appropriate and interested individuals.